WO2012040719A3 - Novel tlr4 inhibitors for the treatment of human infectious and inflammatory disorders - Google Patents

Novel tlr4 inhibitors for the treatment of human infectious and inflammatory disorders Download PDF

Info

Publication number
WO2012040719A3
WO2012040719A3 PCT/US2011/053293 US2011053293W WO2012040719A3 WO 2012040719 A3 WO2012040719 A3 WO 2012040719A3 US 2011053293 W US2011053293 W US 2011053293W WO 2012040719 A3 WO2012040719 A3 WO 2012040719A3
Authority
WO
WIPO (PCT)
Prior art keywords
tlr4
treatment
inflammatory
inflammatory disorders
methods
Prior art date
Application number
PCT/US2011/053293
Other languages
French (fr)
Other versions
WO2012040719A2 (en
Inventor
Peter Wipf
Matthew D. Neal
Chhinder P. Sodhi
David J. Hackam
Original Assignee
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Pittsburgh - Of The Commonwealth System Of Higher Education filed Critical University Of Pittsburgh - Of The Commonwealth System Of Higher Education
Publication of WO2012040719A2 publication Critical patent/WO2012040719A2/en
Publication of WO2012040719A3 publication Critical patent/WO2012040719A3/en
Priority to US13/848,809 priority Critical patent/US9072760B2/en
Priority to US14/717,349 priority patent/US9532999B2/en
Priority to US15/383,625 priority patent/US10300083B2/en
Priority to US15/996,383 priority patent/US10668092B2/en
Priority to US16/386,886 priority patent/US10933077B2/en
Priority to US16/854,196 priority patent/US11413299B2/en
Priority to US17/174,018 priority patent/US20210308162A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides fui pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.
PCT/US2011/053293 2010-09-24 2011-09-26 Novel tlr4 inhibitors for the treatment of human infectious and inflammatory disorders WO2012040719A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US13/848,809 US9072760B2 (en) 2010-09-24 2013-03-22 TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
US14/717,349 US9532999B2 (en) 2010-09-24 2015-05-20 TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
US15/383,625 US10300083B2 (en) 2010-09-24 2016-12-19 TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
US15/996,383 US10668092B2 (en) 2010-09-24 2018-06-01 Compositions and methods for treatment of inflammatory disorders
US16/386,886 US10933077B2 (en) 2010-09-24 2019-04-17 TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
US16/854,196 US11413299B2 (en) 2010-09-24 2020-04-21 Compositions and methods for treatment of inflammatory disorders
US17/174,018 US20210308162A1 (en) 2010-09-24 2021-02-11 Novel tlr4 inhibitors for the treatment of human infectious and inflammatory disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38634510P 2010-09-24 2010-09-24
US61/386,345 2010-09-24
US38733510P 2010-09-28 2010-09-28
US61/387,335 2010-09-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/848,809 Continuation US9072760B2 (en) 2010-09-24 2013-03-22 TLR4 inhibitors for the treatment of human infectious and inflammatory disorders

Publications (2)

Publication Number Publication Date
WO2012040719A2 WO2012040719A2 (en) 2012-03-29
WO2012040719A3 true WO2012040719A3 (en) 2012-05-31

Family

ID=45874436

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/053293 WO2012040719A2 (en) 2010-09-24 2011-09-26 Novel tlr4 inhibitors for the treatment of human infectious and inflammatory disorders

Country Status (1)

Country Link
WO (1) WO2012040719A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102017110935A1 (en) * 2017-05-19 2018-11-22 Eberhard Karls Universität Tübingen Medizinische Fakultät Anti-inflammatory high-purity oligosaccharides
EP3797100A4 (en) 2018-05-23 2022-06-15 Mor Research Applications Ltd. Toll-like receptor 4 (tlr4) inhibitors and use thereof
CN112142761B (en) * 2020-11-08 2022-03-22 江西师范大学 Synthesis method of tetrahydropyrano [3, 2-d ] oxazole ring compound
WO2024010959A1 (en) * 2022-07-07 2024-01-11 University Of Pittsburgh - Of The Commonwealth System Of Higher Education C-glycosides as anti-inflammatory agents

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01180894A (en) * 1988-01-07 1989-07-18 Wako Pure Chem Ind Ltd Novel production of amino sugar derivative
WO2000061555A1 (en) * 1999-04-12 2000-10-19 Gerhard Eisenbrand Indigoid bisindole derivatives
WO2006092049A1 (en) * 2005-03-01 2006-09-08 Simon Fraser University Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof
WO2007106886A2 (en) * 2006-03-15 2007-09-20 Trustees Of Tufts College Fluorinated carbohydrates and their use in tumor visualization, tissue engineering, and cancer chemotherapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01180894A (en) * 1988-01-07 1989-07-18 Wako Pure Chem Ind Ltd Novel production of amino sugar derivative
WO2000061555A1 (en) * 1999-04-12 2000-10-19 Gerhard Eisenbrand Indigoid bisindole derivatives
WO2006092049A1 (en) * 2005-03-01 2006-09-08 Simon Fraser University Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof
WO2007106886A2 (en) * 2006-03-15 2007-09-20 Trustees Of Tufts College Fluorinated carbohydrates and their use in tumor visualization, tissue engineering, and cancer chemotherapy

Also Published As

Publication number Publication date
WO2012040719A2 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
AU2018236800B2 (en) DNA-PK inhibitors
IL207976A0 (en) Novel 02x7r antagonists and their use
JO3199B1 (en) Substituted 5-fluoro-1H-pyrazolopyridines and their use
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
MX2013007558A (en) 1,4 oxazines as bace1 and/or bace2 inhibitors.
TN2012000143A1 (en) Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
MY173994A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
UA111841C2 (en) BENZOTHIAZOL COMPOUNDS AND THEIR PHARMACEUTICAL APPLICATION
ZA201108305B (en) Novel p2x7r antagonists and their use
MX2013007957A (en) 1,4 oxazines as bace1 and/or bace2 inhibitors.
MX2013012053A (en) Inhibitors of viral replication, their process of preparation and their therapeutical uses.
MX2013011691A (en) Inhibitors of viral replication, their process of preparation and their therapeutical uses.
WO2013147649A3 (en) Inhibitors of the pi3k/akt/ikk/nf-kb signalling pathway, pharmaceutically acceptable salts thereof and compositions containing said inhibitors for the prophylaxis and treatment of viral diseases
EA201491028A8 (en) METHOD OF OBTAINING SUBSTITUTED 5-FLUOR-1H-PYRAZOLOPIRIDINES
MX348024B (en) Adamantyl compounds.
TN2014000112A1 (en) Ep1 receptor ligands
WO2012022681A3 (en) Heterocyclyl pyrazolopyrimidine analogues as selective jak inhibitors
IN2015DN02912A (en)
WO2012040719A3 (en) Novel tlr4 inhibitors for the treatment of human infectious and inflammatory disorders
RU2013103507A (en) KELOID TREATMENT
MX2014000963A (en) Substituted bicyclic aromatic carboxamide and urea derivatives as vanilloid receptor ligands.
MX2013002261A (en) Substituted n-phenethyltriazoloneacetamides and use thereof.
MX336278B (en) Compositions and methods for prevention and treatment of wounds.
WO2014108336A8 (en) Pyrazolyl-based carboxamides ii as crac channel inhibitors
GB2503181A (en) Compositions, process of preparation of said compositions and method of treating inflammatory diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11827732

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11827732

Country of ref document: EP

Kind code of ref document: A2